AllPennyStocks.com AstraZeneca-Bristol Myers’ $400B Merger Buzz Cools After Report Denies Talks – ‘There Never Was A Deal To Be ​Done’
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

AstraZeneca-Bristol Myers’ $400B Merger Buzz Cools After Report Denies Talks – ‘There Never Was A Deal To Be ​Done’

According to a Reuters report, a senior source denied merger discussions between AstraZeneca and Bristol Myers Squibb.

Other Penny Stock Movers

When Design Thinking Meets the AI Canvas
Brazilian Developer Jumps 11% as Court Lifts Injunction
Deep Utah Porphyry Intercept Triggers 57% Rally as Drilling Continues Past 550m
Most Popular
{{ index + 1 }}


Back to Top